Earnings
TxCell today reports its fourth quarter 2017 financials and provides an update on its financing.
Entresto, introduced in 2015, got off to a slow start but brought in $507 million in revenue last year.
Narasimhan takes over the role of CEO in February as current CEO Joe Jimenez retires.
The survey of 51 oncologists suggests broad uptake of Imfinzi in advanced lung cancer patients who can’t be treated with surgery.
In an analysis of BMS’ recent clinical history, Industry analysts at Trefis noted that two oncology drugs will be key revenue drivers for the company.
Total product revenues recorded for FY2017 were $747,344 compared to $962,140 in FY2016.
Genentech’s Hemlibra just got approved but is expected to bring in around $2 billion in peak sales.
Valeant is not the only company to recently push reporters to defy the SEC’s orders.
The storm cut $55-$65 million from second-quarter sales. The company previously estimated up to $250 million in costs.
PRESS RELEASES